Physician profile
Jose A Mata
NPI 1962402859
$11,603.06
in general payments reported to CMS, 2019-2025
54 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $1,028 · 2021: $1,374 · 2022: $1,524 · 2023: $2,087 · 2024: $1,774 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,808.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,563.36 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,444.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,296.61 | 2019-2025 | |
| Amgen INC. | $613.18 | 2019-2024 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $568.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $527.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $521.45 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Pfizer INC. | $518.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $460.04 | 2019-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $438.41 | 2021-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $303.76 | 2022-2025 | |
| Corium, LLC | $282.45 | 2023-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $236.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $215.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.13 | 2019-2023 | Trintellix |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $204.93 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.97 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.25 | 2019-2024 | Trulance, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $151.97 | 2019-2021 | |
| Dexcom, INC. | $140.41 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $137.79 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $108.97 | 2024-2025 | Gemtesa, Myfembree |
| Noven Therapeutics, LLC | $101.81 | 2023-2025 | Xelstrym |
| Kowa Pharmaceuticals America, INC. | $92.42 | 2022-2024 | Zoryve, Seglentis, Livalo |
| Phathom Pharmaceuticals, INC. | $85.52 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.64 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $70.39 | 2019-2022 | |
| Verona Pharma, INC. | $68.03 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $59.14 | 2019-2021 | |
| Amarin Pharma, INC. | $54.45 | 2019-2022 | |
| Ardelyx, INC. | $50.71 | 2024-2025 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $49.50 | 2019-2022 | |
| Biogen, INC. | $44.30 | 2021 | |
| Sanofi Pasteur INC. | $39.95 | 2019-2022 | |
| Axsome Therapeutics, INC. | $37.36 | 2023-2025 | Sunosi, Auvelity |
| Abbott Laboratories | $34.72 | 2023-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $33.74 | 2020-2024 | Eliquis |
| Antares Pharma, INC. | $33.01 | 2019-2024 | Xyosted |
| Vifor Pharma, INC. | $32.46 | 2020-2021 | |
| Adlon Therapeutics L.P. | $29.14 | 2019 | |
| Idorsia Pharmaceuticals US INC | $28.40 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $28.24 | 2020-2024 | Contrave, Onzetra Xsail |
| Lundbeck LLC | $24.35 | 2025 | Vyepti |
| Tolmar, INC. | $22.36 | 2024 | |
| Tris Pharma INC | $22.07 | 2023 | Dyanavel Xr |
| Corcept Therapeutics | $20.67 | 2025 | Korlym |
| Tactile Systems Technology INC | $18.98 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.59 | 2020 | |
| Eisai INC. | $18.56 | 2023 | |
| Collegium Pharmaceutical, INC. | $18.46 | 2025 | Jornay Pm |
| Radius Health, INC. | $18.13 | 2019 | |
| Seqirus USA INC | $15.83 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Shire North American Group INC | $12.97 | 2019 | |
| Horizon Therapeutics Plc | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Mata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.